Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024

Written by Customer Service on March 5, 2024. Posted in Public Companies.

5 March 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024 Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces updated clinical data from the First-in-Human Phase 1 trial of the peptide drug conjugate, AVA6000 will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California from 5-10 April 2024. The results will be presented in the Phase 1 Clinical Trials 2 Poster Session on April 9, 2024 as detailed below. Presentation details Title: A Phase I trial of AVA6000,...

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

Written by Customer Service on March 5, 2024. Posted in Public Companies.

Abstract accepted for oral presentation on the evolving EGFR mutational landscape in NSCLC and MasterKey profile of BDTX-1535 addressing a broad spectrum of mutations CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced an upcoming oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California. The presentation will describe real world data of the evolving EGFR mutation landscape in patients with NSCLC, highlighting the increasing relevance of “non-classical” EGFR mutations, which can be found in up to 30% of EGFRm NSCLC. The presentation will also describe...

Tarsus to Participate at Upcoming Investor Conferences

Written by Customer Service on March 5, 2024. Posted in Public Companies.

IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Tarsus will participate in the following conferences: Guggenheim Healthy Altitudes Summit (Telluride, CO) Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, will participate in a fireside chat on Wednesday, March 13, 2024, at 6:30 a.m. PT / 9:30 a.m. ET Barclays Global Healthcare Conference (Miami, FL) Jeff Farrow, Chief Financial Officer and Chief Strategy Officer, and Sesha Neervannan, Chief Operating Officer, will participate in a fireside chat on Tuesday, March 12, 2024, at 12:05 p.m. PT / 3:05 p.m. ET Jefferies Biotech on the Bay Summit...

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting

Written by Customer Service on March 5, 2024. Posted in Public Companies.

Five abstracts accepted for poster presentation highlight company’s differentiated antibody-drug conjugate and multispecific antibody clinical product candidates Strong preclinical activity across multiple FRα-expressing indications for ZW191, a FRα-targeting antibody-drug conjugate Next generation trispecific T cell engager platforms with integrated CD28 costimulation demonstrate durable anti-tumor activity VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced acceptance of five abstracts for poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking...

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

Written by Customer Service on March 5, 2024. Posted in Public Companies.

New preclinical data demonstrating proof-of-concept for the non-signaling gamma-delta T cell CAR (nsCAR) platform candidate targeting CD-33 and CD-123 will be presented. The platform has demonstrated the ability to target cancer cells while sparing healthy tissue when both express the CAR-targeted antigens, which could be used for previously “undruggable” solid and liquid tumor targets. NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced the presentation of new preclinical data for its non-signaling gamma-delta T cell based Chimeric Antigen Receptor T cell (CAR-T) platform, INB-300. The data will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, being held April...

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Written by Customer Service on March 5, 2024. Posted in Public Companies.

BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical Center (BIDMC) at Havard Medical School will present a poster with preclinical data supporting the advancement of TPST-1120 as a potential treatment for renal cell carcinoma (RCC) at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024 in San Diego, CA. Poster presentation details: Title: PPAR-α Antagonist Enhances Immunotherapy and Anti Angiogenic Therapy to Inhibit Murine Renal Cancer Abstract Number: 3045 Date & Time: Monday, April 8, 2024; 1:30 – 5:00 p.m. PT Session...

Immunocore presented two posters at CROI 2024

Written by Customer Service on March 5, 2024. Posted in Public Companies.

Immunocore presented two posters at CROI 2024 Preclinical data highlights importance of TCR biology in development of new HIV treatments (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 05 March 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, presented two posters at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). Poster details Title: Labelled high affinity TCRs for detection of HIV epitopes on infected cells: How low can we go? Presenting author: Zoe WallaceSession: Immune pressure on HIV reservoirs – Poster session-D6Date & time: 4 March 2024,...

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

Written by Customer Service on March 5, 2024. Posted in Public Companies.

WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California. Details for the abstracts and poster presentations are as follows: Abstract Number: 4078Title: WTX-712, a conditionally active IL-21 INDUKINE™ molecule, induces a strong anti-tumor phenotype through a differentiated mechanismSession Category: ImmunologySession Title: Immune Modulation with CytokinesSession Date and...

iSpecimen to Report Full Year 2023 Financial Results on March 13, 2024

Written by Customer Service on March 5, 2024. Posted in Public Companies.

LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the full year ended December 31, 2023 before the market opens on Wednesday, March 13, 2024. The Company will host a conference call and audio webcast that morning at 8:30 a.m. Eastern Time featuring remarks by Tracy Curley, CEO. Event: iSpecimen Year End 2023 Results Conference Call Date: Wednesday, March 13, 2024 Time: 8:30 a.m. Eastern Time Dial in: 1-888-886-7786 (U.S. Toll Free) or 1-416-764-8658 (International) Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1655659&tp_key=8493197d5b For...

23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

Written by Customer Service on March 5, 2024. Posted in Public Companies.

23andMe to give an oral presentation on the genetic signature of ULBP6, the target of 23ME-01473, along with poster presentations of the biology of ULBP6 and mechanism of 23ME-01473, and new non-clinical insights for 23ME-00610, targeting the CD200R1 pathway SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced an oral presentation and two poster presentations on two of the Company’s immuno-oncology programs that will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego, CA, April 5-10, 2024. The oral presentation will detail the use of the 23andMe genetic and health survey database to discover ULBP6, the highest affinity ligand of the NK and...

Day: March 5, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice